EE200300476A - 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon - Google Patents

4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon

Info

Publication number
EE200300476A
EE200300476A EEP200300476A EEP200300476A EE200300476A EE 200300476 A EE200300476 A EE 200300476A EE P200300476 A EEP200300476 A EE P200300476A EE P200300476 A EEP200300476 A EE P200300476A EE 200300476 A EE200300476 A EE 200300476A
Authority
EE
Estonia
Prior art keywords
drug
alpha
methylpropiono
toluidide
pvp
Prior art date
Application number
EEP200300476A
Other languages
English (en)
Estonian (et)
Inventor
Kay Cahill Julie
Frances Bateman Nicola
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27354679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200300476(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0101171A external-priority patent/SE0101171D0/xx
Priority claimed from SE0102957A external-priority patent/SE0102957D0/xx
Priority claimed from SE0103565A external-priority patent/SE0103565D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200300476A publication Critical patent/EE200300476A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200300476A 2001-04-02 2002-03-27 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon EE200300476A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0101171A SE0101171D0 (sv) 2001-04-02 2001-04-02 Pharmaceutical formulation
SE0102957A SE0102957D0 (sv) 2001-09-04 2001-09-04 Pharmaceutical formulation
SE0103565A SE0103565D0 (sv) 2001-10-25 2001-10-25 Pharmaceutical formulation
PCT/GB2002/001439 WO2002080902A1 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp

Publications (1)

Publication Number Publication Date
EE200300476A true EE200300476A (et) 2003-12-15

Family

ID=27354679

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300476A EE200300476A (et) 2001-04-02 2002-03-27 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon

Country Status (21)

Country Link
US (1) US20040138299A1 (de)
EP (1) EP1381358B1 (de)
JP (1) JP2004525164A (de)
KR (1) KR20030087048A (de)
CN (1) CN1536993A (de)
AT (1) ATE324886T1 (de)
BR (1) BR0208421A (de)
CA (1) CA2443040A1 (de)
CZ (1) CZ20032647A3 (de)
DE (1) DE60211139T2 (de)
EE (1) EE200300476A (de)
ES (1) ES2261655T3 (de)
HU (1) HUP0303454A3 (de)
IL (1) IL157955A0 (de)
IS (1) IS6970A (de)
MX (1) MXPA03008999A (de)
NO (1) NO20034386L (de)
NZ (1) NZ528284A (de)
PL (1) PL365330A1 (de)
SK (1) SK12032003A3 (de)
WO (1) WO2002080902A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032225A3 (cs) * 2001-02-27 2003-11-12 Astrazeneca Ab Farmaceutická formulace
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
EP2384749A1 (de) * 2004-11-29 2011-11-09 Novartis AG Dosierungsplan eines S1P-Rezeptoragonisten
WO2006090129A2 (en) * 2005-02-23 2006-08-31 Astrazeneca Ab Bicalutamide for delivering increasing steady state plasma levels
US7785629B2 (en) * 2005-06-21 2010-08-31 Helm Ag Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
EP1912730A2 (de) * 2005-07-28 2008-04-23 Isp Investments Inc. Verfahren zur verbesserung der eigenschaften von sprühgetrockneten pulvern und granulierten materialien und danach erhaltene produkte
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
CA2716448A1 (en) 2008-03-17 2009-09-24 Patrick Brossard Dosing regimen for a selective s1p1 receptor agonist
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
CN103282346B (zh) 2011-01-13 2014-11-19 比皮艾思药物研发有限公司 用于制备苯基氨基甲酸酯衍生物的方法
RU2632659C2 (ru) 2011-12-27 2017-10-09 Байо-Фарм Солюшнс Ко., Лтд. Фенилкарбаматные соединения для применения в предупреждении или лечении эпилепсии
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
CN105358139B (zh) 2013-07-03 2020-10-16 Lts罗曼治疗方法有限公司 具有电子元件的经皮治疗系统
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
JP6573913B2 (ja) * 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
RS62421B1 (sr) 2014-12-05 2021-10-29 Aragon Pharmaceuticals Inc Anti-kancerogeni sastavi
CN114886852A (zh) 2014-12-05 2022-08-12 阿拉贡药品公司 抗癌组合物
WO2016090101A1 (en) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Anticancer compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2181358A1 (en) * 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia

Also Published As

Publication number Publication date
WO2002080902A1 (en) 2002-10-17
NO20034386L (no) 2003-11-28
CN1536993A (zh) 2004-10-13
NO20034386D0 (no) 2003-10-01
US20040138299A1 (en) 2004-07-15
CZ20032647A3 (cs) 2004-09-15
JP2004525164A (ja) 2004-08-19
IL157955A0 (en) 2004-03-28
MXPA03008999A (es) 2004-02-12
ATE324886T1 (de) 2006-06-15
HUP0303454A3 (en) 2005-12-28
ES2261655T3 (es) 2006-11-16
NZ528284A (en) 2005-04-29
DE60211139T2 (de) 2007-03-01
KR20030087048A (ko) 2003-11-12
HUP0303454A2 (hu) 2004-01-28
EP1381358B1 (de) 2006-05-03
SK12032003A3 (sk) 2004-03-02
IS6970A (is) 2003-09-29
EP1381358A1 (de) 2004-01-21
PL365330A1 (en) 2004-12-27
CA2443040A1 (en) 2002-10-17
BR0208421A (pt) 2004-03-30
DE60211139D1 (de) 2006-06-08

Similar Documents

Publication Publication Date Title
NO20034386D0 (no) Fast farmasöytisk preparat omfattende 4-cyano-trifluor-3-(4- fluorfenylsulfonyl)-2-hydroksy-2-metylpropiono-m-toluidid og PVP
AR032912A1 (es) Formulacion farmaceutica
DE60332629D1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yi)aminderivate
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
DK1256339T3 (da) Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
MXPA05011076A (es) Derivados de quinazolina para el tratamiento de cancer.
TW200505452A (en) Chemical compounds
SE0103424D0 (sv) Pharmaceutical formulation
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
SE0102440D0 (sv) New compound
BR0017120A (pt) Composição farmacêutica
BR0001201A (pt) Composto ( poli ) tia-alcinóicos, composição cosmética, utilização de uma composição cosmética, utilização de um composto e composição farmacêutica
SE0103839D0 (sv) Pharmaceutical formulation & product
PL368686A1 (en) Novel aminobenzoephenones
SE0103838D0 (sv) Pharmaceutical formulation & product
SE0102887D0 (sv) New formulation
BRPI0410657A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0213463A (pt) Composições farmacêuticas contendo macrólidos